Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Roflumilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arcutis Submits sNDA for ZORYVE in Infants with Atopic Dermatitis
    Arcutis Submits sNDA for ZORYVE in Infants with Atopic Dermatitis

    27 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7212866

    FIRSTWORD PHARMA
    27 Apr 2026
    Share Share
    Arcutis Submits Supplemental NDA to FDA for ZORYVE Cream 0.05%
    Arcutis Submits Supplemental NDA to FDA for ZORYVE Cream 0.05%

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281570/0/en/arcutis-submits-supplemental-new-drug-application-to-the-fda-for-zoryve-roflumilast-cream-0-05-to-expand-indication-for-treatment-of-atopic-dermatitis-to-infants-down-to-3-months.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Arcutis Presents Phase 2 Data on Infant Atopic Dermatitis at AAD
    Arcutis Presents Phase 2 Data on Infant Atopic Dermatitis at AAD

    28 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/28/3264182/0/en/Arcutis-Presents-New-Phase-2-Results-in-Infants-with-Atopic-Dermatitis-in-Late-Breaking-Session-Today-at-the-2026-American-Academy-of-Dermatology-Annual-Meeting.html

    GLOBENEWSWIRE
    28 Mar 2026
    Share Share
    Arcutis To Unveil New Clinical Data At 2026 Aad Annual Meeting
    Arcutis To Unveil New Clinical Data At 2026 Aad Annual Meeting

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258097/0/en/Arcutis-to-Present-New-Clinical-Data-in-a-Late-Breaking-Podium-Presentation-and-Scientific-Posters-at-the-2026-American-Academy-of-Dermatology-Annual-Meeting.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Arcutis Publishes Positive Long-Term Data On ZORYVE Cream
    Arcutis Publishes Positive Long-Term Data On ZORYVE Cream

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3252886/0/en/Arcutis-Announces-Publication-of-Positive-Long-Term-Safety-and-Efficacy-Data-with-ZORYVE-roflumilast-Cream-0-05-for-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis-in-Children-Ages.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    Arcutis Elevates Mas Matsuda To EVP & Chief Legal Officer
    Arcutis Elevates Mas Matsuda To EVP & Chief Legal Officer

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250243/0/en/Arcutis-Announces-Promotion-of-Mas-Matsuda-to-Executive-Vice-President-and-Chief-Legal-Officer-to-Support-Next-Phase-of-Growth.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.